.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech hopes to provide on the Nasdaq under the symbolic representation "BIOA," according to documentations filed with the Stocks and also Substitution Compensation. The provider has certainly not publicly shared an anticipated financial amount for the offering.The clinical-stage firm boasts lead prospect azelaprag, a by mouth delivered little molecule slated to enter into period 2 testing in combination along with semaglutide-- offered through Novo Nordisk under trademark name Wegovy for weight loss-- in the 1st fifty percent of upcoming year. Semaglutide is also sold as Ozempic and also Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is designed to integrate properly with GLP-1 drugs, improving fat burning while protecting muscle mass. The investigational drug was discovered to be well-tolerated amongst 265 individuals across 8 phase 1 tests, depending on to BioAge.Recently, BioAge achieved the help of Lilly to operate a trial integrating azelaprag with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes mellitus as Mounjaro and Zepbound for fat loss. The partners are presently performing a phase 2 test of azelaprag and tirzepatide, along with topline results expected in the third fourth of 2025.The biotech is additionally planning a the hormone insulin sensitiveness proof-of-concept test examining azelaprag as a monotherapy in the very first fifty percent of following year to support potential indication expansion. In addition, the provider plans to ask the FDA for authorization in the second one-half of 2025 to launch individual testing for an NLRP3 prevention targeting metabolic illness as well as neuroinflammation.BioAge's anticipated move to everyone market follows a small uptick in planned biotech IPOs coming from Bicara Therapies and Zenas Biopharma. Zooming out, the latest IPO yard is actually a "mixed picture," along with premium firms still debuting on everyone markets, just in lowered amounts, according to PitchBook.